• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恩度治疗鼻咽癌放疗相关鼻咽坏死2例报告并文献复习

Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review.

作者信息

Tang Jie, Li Xiu-Wen, Wu Yong, Su Zhen, He Yan, Sun Xue-Wen, Cao Xiao-Long, Li Yi-Hua, Wang Bi-Cheng, Zou Guo-Rong

机构信息

Department of Oncology, Panyu Central Hospital, Cancer Institute of Panyu, Guangzhou, Guangdong 511400, P.R. China.

Department of Cardiology, Panyu Central Hospital, Guangzhou, Guangdong 511400, P.R. China.

出版信息

Mol Clin Oncol. 2023 Jun 13;19(1):57. doi: 10.3892/mco.2023.2653. eCollection 2023 Jul.

DOI:10.3892/mco.2023.2653
PMID:37359714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10288433/
Abstract

Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.

摘要

放射性鼻咽坏死(RRNN)是鼻咽癌(NPC)患者中一种罕见且常致命的并发症。目前,对于RRNN尚无推荐的标准治疗方法。传统保守治疗的效果欠佳,且经验不足的医生无法对RRNN进行手术治疗。在本研究中,评估了恩度在两名RRNN患者中的应用。两名RRNN患者在番禺中心医院(中国广州)肿瘤科接受治疗。分别对一名男性患者和一名女性患者静脉注射恩度(第1天至第7天每天15 mg,每三周一次),男性患者注射四个周期,女性患者注射七个周期。使用磁共振成像(MRI)和鼻咽镜评估恩度的疗效。两名患者经恩度治疗后RRNN症状均得到缓解。MRI和鼻咽镜分析显示,鼻咽部坏死明显减轻,鼻咽溃疡愈合。恩度有可能成为治疗RRNN患者的一种新型有效疗法。然而,需要进行临床试验来证实本研究的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/6fe84608d071/mco-19-01-02653-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/929ba8dbe1bf/mco-19-01-02653-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/2191771a29c5/mco-19-01-02653-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/73f505a3995e/mco-19-01-02653-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/5d39d2f91b23/mco-19-01-02653-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/b847a5cf372b/mco-19-01-02653-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/c5d97fb38e7f/mco-19-01-02653-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/6fe84608d071/mco-19-01-02653-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/929ba8dbe1bf/mco-19-01-02653-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/2191771a29c5/mco-19-01-02653-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/73f505a3995e/mco-19-01-02653-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/5d39d2f91b23/mco-19-01-02653-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/b847a5cf372b/mco-19-01-02653-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/c5d97fb38e7f/mco-19-01-02653-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83f3/10288433/6fe84608d071/mco-19-01-02653-g06.jpg

相似文献

1
Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review.恩度治疗鼻咽癌放疗相关鼻咽坏死2例报告并文献复习
Mol Clin Oncol. 2023 Jun 13;19(1):57. doi: 10.3892/mco.2023.2653. eCollection 2023 Jul.
2
Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.在局部晚期鼻咽癌的治疗中,调强放疗联合恩度与调强放疗联合化疗疗效相似,但急性不良反应较轻。
Medicine (Baltimore). 2018 Jun;97(25):e11118. doi: 10.1097/MD.0000000000011118.
3
The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.恩度联合放化疗治疗局部晚期复发性鼻咽癌患者的疗效与安全性。
Oncotarget. 2015 Oct 20;6(32):33926-34. doi: 10.18632/oncotarget.5271.
4
Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.调强放疗联合恩度对比调强放疗联合化疗治疗局部晚期鼻咽癌的长期疗效及不良反应:一项回顾性研究。
Ann Palliat Med. 2021 Nov;10(11):11891-11900. doi: 10.21037/apm-21-3018.
5
A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.一项比较标准放化疗联合或不联合重组人血管内皮抑制素注射液(恩度)治疗局部晚期鼻咽癌的 II 期多中心随机对照临床试验:长期结果更新。
Curr Probl Cancer. 2020 Feb;44(1):100492. doi: 10.1016/j.currproblcancer.2019.06.007. Epub 2019 Jul 2.
6
Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study.重组人内皮抑素注射液(恩度)联合PF化疗及序贯调强放疗治疗局部晚期鼻咽癌耐受性良好且可改善预后:一项随机、开放、多中心II期临床研究
Am J Cancer Res. 2022 Oct 15;12(10):4622-4636. eCollection 2022.
7
Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report.恩度联合短期高压氧治疗三阴性乳腺癌脑放射性坏死成功:一例报告
Onco Targets Ther. 2019 Apr 10;12:2729-2735. doi: 10.2147/OTT.S190409. eCollection 2019.
8
Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update.恩度联合吉西他滨和顺铂化疗治疗转移性鼻咽癌患者:最新进展
Transl Oncol. 2018 Apr;11(2):286-291. doi: 10.1016/j.tranon.2018.01.002. Epub 2018 Feb 3.
9
Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models.重组人血管内皮抑制素使移植人鼻咽癌模型的肿瘤血管正常化并增强放射反应。
PLoS One. 2012;7(4):e34646. doi: 10.1371/journal.pone.0034646. Epub 2012 Apr 9.
10
Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models.恩度联合放疗对人鼻咽癌小鼠移植瘤模型的抗肿瘤活性
Oncol Lett. 2012 Nov;4(5):976-980. doi: 10.3892/ol.2012.856. Epub 2012 Aug 8.

引用本文的文献

1
Pre-treatment and post-treatment nasopharyngeal carcinoma imaging: imaging updates, pearls and pitfalls.鼻咽癌治疗前和治疗后的影像学检查:影像学进展、要点与陷阱
Neuroradiology. 2025 Apr;67(4):1023-1047. doi: 10.1007/s00234-025-03596-z. Epub 2025 Apr 11.

本文引用的文献

1
Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial.晚期实体瘤患者单次或多次输注重组人血管内皮抑制素的耐受性和药代动力学:一项 I 期临床试验。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211064434. doi: 10.1177/15330338211064434.
2
Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study.非鼻咽癌高发地区调强放疗鼻咽癌患者的长期生存结果和不良反应:一项基于人群的回顾性研究。
BMJ Open. 2021 Aug 2;11(8):e045417. doi: 10.1136/bmjopen-2020-045417.
3
Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era.
比较调强放疗时代 UICC/AJCC 第 7 版和第 8 版鼻咽癌分期系统。
BMC Cancer. 2021 Mar 30;21(1):327. doi: 10.1186/s12885-021-08036-8.
4
Efficacy of endostar combined with transcatheter arterial chemoembolization and analysis of vascular endothelial factor and C-reactive protein levels in patients with advanced hepatocellular carcinoma under contrast enhanced ultrasound.恩度联合经动脉化疗栓塞术治疗晚期肝细胞癌的疗效及超声造影下血管内皮生长因子和C反应蛋白水平分析
J BUON. 2020 Jan-Feb;25(1):407-414.
5
The development of a nomogram to predict post-radiation necrosis in nasopharyngeal carcinoma patients: a large-scale cohort study.预测鼻咽癌患者放疗后坏死的列线图的开发:一项大规模队列研究。
Cancer Manag Res. 2019 Jul 8;11:6253-6263. doi: 10.2147/CMAR.S197841. eCollection 2019.
6
Successful treatment of brain radiation necrosis resulting from triple-negative breast cancer with Endostar and short-term hyperbaric oxygen therapy: a case report.恩度联合短期高压氧治疗三阴性乳腺癌脑放射性坏死成功:一例报告
Onco Targets Ther. 2019 Apr 10;12:2729-2735. doi: 10.2147/OTT.S190409. eCollection 2019.
7
Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.调强放疗治疗复发性鼻咽癌的长期生存和晚期并发症。
BMC Cancer. 2018 Nov 20;18(1):1139. doi: 10.1186/s12885-018-5055-5.
8
Endoscopic sequestrectomy for skull base osteoradionecrosis in nasopharyngeal carcinoma patients: a 10‑year experience.内镜下清创术治疗鼻咽癌患者颅底放射性骨坏死:10 年经验。
Int J Clin Oncol. 2019 Mar;24(3):248-255. doi: 10.1007/s10147-018-1354-8. Epub 2018 Nov 9.
9
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.恩度联合化疗对晚期高分化胰腺神经内分泌肿瘤的疗效
Medicine (Baltimore). 2018 Nov;97(45):e12750. doi: 10.1097/MD.0000000000012750.
10
Osteoradionecrosis of the Skull Base in Nasopharyngeal Carcinoma: Incidence and Risk Factors.颅底放射性骨坏死与鼻咽癌:发生率及危险因素。
Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):552-555. doi: 10.1016/j.ijrobp.2018.06.027. Epub 2018 Jun 28.